Sciarra, A.; Santarelli, V.; Santodirocco, L.; Frisenda, M.; Salciccia, S.; Casale, P.; Forte, F.; Mariotti, G.; Moriconi, M.; Cattarino, S.;
et al. Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients? Curr. Oncol. 2023, 30, 8054-8067.
https://doi.org/10.3390/curroncol30090584
AMA Style
Sciarra A, Santarelli V, Santodirocco L, Frisenda M, Salciccia S, Casale P, Forte F, Mariotti G, Moriconi M, Cattarino S,
et al. Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients? Current Oncology. 2023; 30(9):8054-8067.
https://doi.org/10.3390/curroncol30090584
Chicago/Turabian Style
Sciarra, Alessandro, Valerio Santarelli, Lorenzo Santodirocco, Marco Frisenda, Stefano Salciccia, Paolo Casale, Flavio Forte, Gianna Mariotti, Martina Moriconi, Susanna Cattarino,
and et al. 2023. "Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients?" Current Oncology 30, no. 9: 8054-8067.
https://doi.org/10.3390/curroncol30090584
APA Style
Sciarra, A., Santarelli, V., Santodirocco, L., Frisenda, M., Salciccia, S., Casale, P., Forte, F., Mariotti, G., Moriconi, M., Cattarino, S., Sciarra, B., Bevilacqua, G., & Gentilucci, A.
(2023). Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients? Current Oncology, 30(9), 8054-8067.
https://doi.org/10.3390/curroncol30090584
